A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorWayshine Biopharm, Inc.
About this trial
This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .
Eligibility criteria
Qualifiers
Age 18-75 years old (including the threshold value), gender is not limited;
Locally advanced or metastatic NSCLC confirmed by pathology;
Patients who have been genetically tested to carry EGFR sensitive mutations;
Blood samples must be provided for testing and must be taken during or after disease progression following the last EGFR TKI inhibitor treatment;
Disqualifiers
Received chemotherapy, radiotherapy, biological therapy, targeted therapy, endocrine therapy, immunotherapy, or other anti-tumor drug treatments within 4 weeks before the first administration of the study drug.
Have previously received more than one EGFR-TKI inhibitor;
Received other unlisted clinical study drugs or treatments within 4 weeks before the first administration.
Received major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks before the first administration, or require elective surgery during the trial period.
Trial design
Treatments tested in this trial
- WSD0922-FU
Treatment groups
100 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov